Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US

BACKGROUND: In July 2019, bevacizumab-awwb and trastuzumab-anns were marketed in the USA as the first therapeutic oncology biosimilars. We aimed to investigate the initial real-world use of bevacizumab-awwb and trastuzumab-anns for cancer management in US oncology practices. METHODS: A retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Ran, Mahtani, Reshma L., Accortt, Neil, Lawrence, Tatiana, Sandschafer, Darcie, Loaiza-Bonilla, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734207/
https://www.ncbi.nlm.nih.gov/pubmed/35003333
http://dx.doi.org/10.1177/17588359211041961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734207/
https://www.ncbi.nlm.nih.gov/pubmed/35003333
http://dx.doi.org/10.1177/17588359211041961

Ejemplares similares